Z6尊龙

集团群站
  • 天道医药中国
  • 天道医药英国
  • 天道医药波兰
  • 天道医药意大利
  • 天道医药西班牙
  • 天道医药德国
  • 天道医药美国
  • 赛湾生物
  • SPL
Z6尊龙·凯时(中国)人生就是搏! Z6尊龙·凯时(中国)人生就是搏!

更专心 ,只为更好地护佑康健

我们将对患者的眷注体现在药物生产和运转的全历程细节把控中
Z6尊龙·凯时(中国)人生就是搏!
Z6尊龙·凯时(中国)人生就是搏!
Z6尊龙·凯时(中国)人生就是搏!
Z6尊龙·凯时(中国)人生就是搏!
Inhixa
通用名:
依诺肝素钠注射液
销售市�。�
欧盟非波兰
规格:
2,000?IU?(20?mg)/0.2?mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000?IU (120?mg)/0.8?mL 15,000?IU (150?mg)/1?mL 30,000?IU (300?mg)/3?mL 50,000?IU (500?mg)/5?mL 100,000 IU (1000 mg)/10 mL
顺应症:
Inhixa is indicated in adults for:

·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

·Acute coronary syndrome:

·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).

【网站地图】【sitemap】